Stem cell-based therapy for human diseases

Signal Transduction and Targeted Therapy, Journal Year: 2022, Volume and Issue: 7(1)

Published: Aug. 6, 2022

Abstract Recent advancements in stem cell technology open a new door for patients suffering from diseases and disorders that have yet to be treated. Stem cell-based therapy, including human pluripotent cells (hPSCs) multipotent mesenchymal (MSCs), has recently emerged as key player regenerative medicine. hPSCs are defined self-renewable types conferring the ability differentiate into various cellular phenotypes of body, three germ layers. MSCs progenitor possessing self-renewal (limited vitro) differentiation potential lineages, according International Society Cell Gene Therapy (ISCT). This review provides an update on recent clinical applications using either or derived bone marrow (BM), adipose tissue (AT), umbilical cord (UC) treatment diseases, neurological disorders, pulmonary dysfunctions, metabolic/endocrine-related reproductive skin burns, cardiovascular conditions. Moreover, we discuss our own trial experiences targeted therapies setting, propose MSC origin concept how may contribute role downstream applications, with ultimate objective facilitating translational research medicine applications. The mechanisms discussed here support proposed hypothesis BM-MSCs potentially good candidates brain spinal injury treatment, AT-MSCs disorder regeneration, UC-MSCs disease acute respiratory distress syndrome treatment.

Language: Английский

---

Clinical application of mesenchymal stem cell in regenerative medicine: a narrative review

Stem Cell Research & Therapy, Journal Year: 2022, Volume and Issue: 13(1)

Published: July 28, 2022

Abstract The multipotency property of mesenchymal stem cells (MSCs) has attained worldwide consideration because their immense potential for immunomodulation and therapeutic function in tissue regeneration. MSCs can migrate to injury areas contribute immune modulation, secrete anti-inflammatory cytokines hide themselves from the system. Certainly, various investigations have revealed anti-inflammatory, anti-aging, reconstruction, wound healing potentials many vitro vivo models. Moreover, current progresses field biology facilitated progress particular guidelines quality control approaches, which eventually lead clinical application MSCs. In this literature, we provided a brief overview immunoregulatory characteristics immunosuppressive activities addition, discussed enhancement, utilization, responses neural, liver, kidney, bone, heart diseases, healing.

Language: Английский

---

Allogeneic Stem Cell Therapy for Acute Ischemic Stroke

JAMA Neurology, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 16, 2024

Importance Cell therapy is a promising treatment approach for stroke and other diseases. However, it unknown whether MultiStem (HLCM051), bone marrow–derived, allogeneic, multipotent adult progenitor cell product, has the potential to treat ischemic stroke. Objective To assess efficacy safety of when administered within 18 36 hours onset. Design, Setting, Participants The Treatment Evaluation Acute Stroke Using Regenerative Cells (TREASURE) multicenter, double-blind, parallel-group, placebo-controlled phase 2/3 randomized clinical trial was conducted at 44 academic centers in Japan between November 15, 2017, March 29, 2022. Inclusion criteria were age 20 years or older, presence acute (National Institutes Health Scale [NIHSS] score 8-20 baseline), confirmed infarction involving cerebral cortex measuring more than 2 cm on major axis (determined with diffusion-weighted magnetic resonance imaging), modified Rankin (mRS) 0 1 before Data analysis performed May 9 August Exposure Patients randomly assigned either intravenous single unit 1.2 billion cells placebo Main Outcomes Measures primary end points excellent outcome day 90, measured as composite less, NIHSS Barthel index 95 greater. secondary 365, mRS distribution days 90 90. Statistical using Cochran-Mantel-Haenszel test. Results This study included 206 patients (104 received 102 placebo). Their mean 76.5 (range, 35-95) years, half men (112 [54.4%]). There no between-group differences points. proportion outcomes did not differ significantly groups (12 [11.5%] vs 10 [9.8%], P = .90; adjusted risk difference, 0.5% [95% CI, −7.3% 8.3%]). frequency adverse events similar groups. Conclusions Relevance In this trial, administration allogeneic onset safe but improve short-term outcomes. Further research needed determine beneficial effect who meet specific criteria, indicated by exploratory analyses study. Trial Registration ClinicalTrials.gov Identifier: NCT02961504

Language: Английский

---

Final Results of Allogeneic Adipose Tissue–Derived Mesenchymal Stem Cells in Acute Ischemic Stroke (AMASCIS): A Phase II, Randomized, Double-Blind, Placebo-Controlled, Single-Center, Pilot Clinical Trial

Cell Transplantation, Journal Year: 2022, Volume and Issue: 31

Published: Jan. 1, 2022

Acute ischemic stroke is currently a major cause of disability despite improvement in recanalization therapies. Stem cells represent promising innovative strategy focused on reduction neurologic sequelae by enhancement brain plasticity. We performed phase IIa, randomized, double-blind, placebo-controlled, single-center, pilot clinical trial. Patients aged ≥60 years with moderate to severe (National Institutes Health Stroke Scale [NIHSS] 8–20) were randomized (1:1) receive intravenous adipose tissue–derived mesenchymal stem (AD-MSCs) or placebo within the first 2 weeks onset. The primary outcome was safety, evaluating adverse events (AEs), and systemic complications, tumor development. secondary evaluated treatment efficacy measuring modified Rankin (mRS), NIHSS, infarct size, blood biomarkers. report final trial results after 24 months follow-up. Recruitment began December 2014 stopped 2017 19 20 planned patients included. Six did not study treatment: two due technical issues four for acquiring exclusion criteria randomization. sample composed 13 (4 receiving AD-MSCs 9 placebo). One patient group died week delivery sepsis. Two non-treatment-related serious AEs occurred AD-MSC nine group. total number complications similar between groups. No injection-related registered, nor At follow-up, showed nonsignificantly lower median NIHSS score (interquartile range, 3 [3–5.5] vs 7 [0–8]). Neither had differences mRS scores throughout follow-up visits up month 24. Therefore, from safe at

Language: Английский

---

Mesenchymal stem cell therapy for neurological disorders: The light or the dark side of the force?

Frontiers in Bioengineering and Biotechnology, Journal Year: 2023, Volume and Issue: 11

Published: Feb. 28, 2023

Neurological disorders are recognized as major causes of death and disability worldwide. Because this, they represent one the largest public health challenges. With awareness massive burden associated with these disorders, came recognition that treatment options were disproportionately scarce and, oftentimes, ineffective. To address problems, modern research is increasingly looking into novel, more effective methods to treat neurological patients; which cell-based therapies. In this review, we present a critical analysis features, challenges, prospects stem cell types can be employed numerous disorders—mesenchymal cells (MSCs). Despite fact several studies have already established safety MSC-based approaches, there still some reservations within field regarding their immunocompatibility, heterogeneity, stemness stability, range adverse effects—one tumor-promoting ability. We additionally examine MSCs’ mechanisms action respect in vitro vivo well detail findings past ongoing clinical trials for Parkinson’s Alzheimer’s disease, ischemic stroke, glioblastoma multiforme, multiple sclerosis. Finally, review discusses therapeutics form biomaterials, use electromagnetic fields enhance proliferation differentiation neuronal cells.

Language: Английский

---

Role of Adipose-Derived Mesenchymal Stem Cells in Bone Regeneration

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(12), P. 6805 - 6805

Published: June 20, 2024

Bone regeneration involves multiple factors such as tissue interactions, an inflammatory response, and vessel formation. In the event of diseases, old age, lifestyle, or trauma, bone can be impaired which could result in a prolonged healing duration requiring external intervention for repair. Currently, grafts hold golden standard regeneration. However, several limitations hinder its clinical applications, e.g., donor site morbidity, insufficient volume, uncertain post-operative outcomes. engineering, involving stem cells seeded onto scaffolds, has thus been promising treatment alternative Adipose-derived mesenchymal (AD-MSCs) are known to therapeutic value various conditions have displayed feasibility significant effectiveness due their ease isolation, non-invasive, abundance quantity, osteogenic capacity. Notably, vitro studies showed AD-MSCs holding high proliferation capacity, multi-differentiation potential through release variety factors, extracellular vesicles, allowing them repair damaged tissues. vivo favoring better vascularization integration while presence scaffolds enhanced osteogenesis AD-MSCs, yielding optimal formation Effective requires interplay both (material, pore size) improve vasculogenic This review presents advances applications focusing on vitro, vivo, engineering.

Language: Английский

---

The 2022 yearbook of Neurorestoratology

Journal of Neurorestoratology, Journal Year: 2023, Volume and Issue: 11(2), P. 100054 - 100054

Published: April 27, 2023

There was much progress in the field of Neurorestoratology year 2022. It included highlighting advances understanding pathogenesis neurological diseases, neurorestorative mechanisms, and clinical treatments as compiled 2022 yearbook Neurorestoratology. is still controversy about whether amyloid β-protein tau protein deposition are reasons for or results Alzheimer's disease (AD) pathology. The fabricated images important key articles that speculated on AD were found. Cholinergic deficiency decrease loss strength glutamatergic synapse, limited failing bidirectional cholinergic upregulation early cognitive impairment, progressive posterior-to-anterior cortical denervation could result appearance AD. Exploration mechanisms found more detail ways neuromodulation, immunomodulation, neurogenesis, neural network circuitry reconstruction, neuroprotection, nervous structural repair, neuroplasticity. Several kinds cell therapies diseases showed effects open-label and/or non-randomized studies trials. However, mesenchymal stromal cells mononuclear did not demonstrate improve quality life patients with neurodegenerative neurotrauma including stroke, spinal cord injury (SCI), amyotrophic lateral sclerosis randomized, double-blind, placebo-controlled trials (RDPCTs). Clinical through neurostimulation/neuromodulation brain–computer/machine interface yielded positive AD, Parkinson's disease, SCI, cerebral palsy, other RDPCTs. Neurorestorative surgery, pharmaceutical therapy interventions have demonstrated various considered incurable Thus, this year, additional guidelines, assessment scales, standards set up revised. These guidelines brain trauma (2022 China version), neurorestoration (IANR/CANR 2022), SCI dysfunction rating scale (SCIDQLRS) (IANR version). varying therapeutic strategies higher evidence-based medicine now benefiting currently diseases. Hopefully some them may become routine these near future.

Language: Английский

---

Potential applications of mesenchymal stem cells and their derived exosomes in regenerative medicine

Expert Opinion on Biological Therapy, Journal Year: 2023, Volume and Issue: 23(6), P. 491 - 507

Published: May 6, 2023

Regenerative medicine involves the replacement of damaged cells, tissues, or organs to restore normal function. Mesenchymal stem cells (MSCs) and exosomes secreted by MSCs have unique advantages that make them a suitable candidate in field regenerative medicine.

Language: Английский

---

Adipose-derived mesenchymal stromal cells in clinical trials: Insights from single-cell studies

Life Sciences, Journal Year: 2024, Volume and Issue: 351, P. 122761 - 122761

Published: June 12, 2024

Mesenchymal Stromal Cells (MSCs) offer tremendous potential for the treatment of various diseases and their healing properties have been explored in hundreds clinical trials. These trails primarily focus on immunological neurological disorders, as well regenerative medicine. Adipose tissue is a rich source mesenchymal stromal cells methods to obtain culture adipose-derived MSCs (AD-MSCs) established. Promising results from pre-clinical testing AD-MSCs activity prompted trials that further led approval complex perianal fistulas Crohn's disease subcutaneous defects. However, AD-MSC heterogeneity along with manufacturing protocols or different strategies boost create need standardized quality control procedures safety assessment intended cell product. High-resolution transcriptomic recently gaining attention, they deliver insight into gene expression profiles individual cells, helping deconstruct cellular hierarchy differentiation trajectories, understand cell-cell interactions within tissues. This article presents comprehensive overview completed evaluating efficacy treatment, together current single-cell studies human AD-MSC. Furthermore, our work emphasizes increasing significance research elucidating mechanisms action predicting therapeutic effects.

Language: Английский

---

Revolutionizing Stroke Recovery: Unveiling the Promise of Stem Cell Therapy

Drug Design Development and Therapy, Journal Year: 2024, Volume and Issue: Volume 18, P. 991 - 1006

Published: March 1, 2024

Stem cells, renowned for their unique regenerative capabilities, present significant hope in treating stroke, a major cause of disability globally.This review offers detailed analysis stem cell applications stroke (ischemic and hemorrhagic) recovery.It examines therapies based on autologous (patient-derived), allogeneic (donor-derived), Granulocyte-Colony Stimulating Factor (G-CSF) focusing types such as Mesenchymal Stem/Stromal Cells (MSCs), Bone Marrow Mononuclear (BMMSCs), Neural Stem/Progenitor (NSCs).The paper compiles clinical trial data to evaluate effectiveness safety addresses the ethical concerns these innovative treatments.By explaining mechanisms cell-induced neurological repair, this underscores cells' potential revolutionizing rehabilitation suggests avenues future research.

Language: Английский

---